Maze Therapeutics, Inc. 8-K

What Happened

• Maze Therapeutics, Inc. announced on April 21, 2026 that it entered into an underwriting agreement with Leerink Partners LLC to sell 5,540,000 shares of common stock and pre-funded warrants to purchase 850,000 shares.
• The public offering price is $23.50 per share and $23.499 per pre-funded warrant (reflecting a $0.001 exercise price). The company estimates net proceeds of approximately $144.7 million after underwriting discounts, commissions and offering expenses. The pre-funded warrants are exercisable immediately and include ownership caps (default 4.99% or 9.99% at holder election, adjustable up to 19.99% with 61 days’ notice).
• The offering is being made under Maze’s automatic shelf registration statement on Form S-3 (effective Feb 4, 2026); related documents including the underwriting agreement, warrant form and legal opinion were filed with the 8-K.

Key Details

• Offering size: 5,540,000 common shares + pre-funded warrants for 850,000 shares.
• Prices: $23.50 per share; $23.499 per pre-funded warrant (exercise price $0.001).
• Estimated net proceeds: ≈ $144.7 million (after fees/expenses).
• Use of proceeds: primarily to advance R&D for MZE829 (APOL1-mediated kidney disease) and MZE782 (PKU and chronic kidney disease), plus general corporate purposes; company expects cash runway into 2029 based on current plan.

Why It Matters

• Financing impact: This offering provides Maze with fresh capital to fund development of its lead programs (MZE829 and MZE782) and operations through its stated 2029 runway, reducing near-term funding risk.
• Dilution and ownership: Issuance of new shares and potential exercise of pre-funded warrants will dilute existing shareholders; exercise limits on pre-funded warrants are in place to restrict large ownership changes.
• Execution signal: Raising capital via a marketed offering and filing the related documents signals that the company is prioritizing advancement of clinical programs and strengthening its cash position. Investors should weigh the benefit of extended funding against dilution from the new securities.